title: Effect of recombinant interferon-alpha2C on reticuloendothelial function in patients with thrombocytosis.
abstract: The aim of the study was to investigate the influence of recombinant interferon-alpha 2C (rIFN-alpha 2C) on the in vivo Fc-dependent phagocytic activity of the reticuloendothelial (RE) system. Fourteen patients with excessive thrombocytosis due to myeloproliferative disorders were studied before and 3 months after initiation of therapy. RE function was determined by measuring the clearance of autologous red blood cells (RBC) labeled with 51Cr and sensitized with anti-D antibody. Eleven of the 14 patients responded to rIFN-alpha 2 treatment (platelets, less than 440 X 10(9)/liter). Rather in contrast to a shortening of platelet half-life and an increase (trendwise) in platelet-bound IgG, rIFN-alpha 2 caused a significant impairment of RE function. Although this finding could in part be accounted for by the treatment-related decrease in splenic volume, statistical analysis revealed a direct influence of rIFN-alpha 2 on RBC clearance (p less than 0.01). Our study results might be explained by an interferon (IFN)-induced, intensified expression of Fc receptors on platelet (and leukocyte) surfaces, possibly enhancing unspecific binding of IgG to their cellular membranes. The subsequent increased platelet uptake may lead to an overloading of the RE system causing impaired reactions to additional stimuli such as IgG-coated RBC.
authors.affiliation: Department of Internal Medicine II, University School of Medicine, Vienna, Austria.
authors.forename: W
authors.initials: W
authors.lastname: Scheithauer
authors.forename: H
authors.initials: H
authors.lastname: Gisslinger
authors.forename: E M
authors.initials: EM
authors.lastname: Temsch
authors.forename: M
authors.initials: M
authors.lastname: Linkesch
authors.forename: W
authors.initials: W
authors.lastname: Linkesch
authors.forename: H
authors.initials: H
authors.lastname: Ludwig
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000502:physiology; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012157:Mononuclear Phagocyte System / Q000187:drug effects*; D010587:Phagocytosis / Q000187:drug effects; D011994:Recombinant Proteins; D012074:Remission Induction; D013922:Thrombocytosis / Q000097:blood / Q000188:drug therapy*
chemical_list: D007141:Immunoglobulin Fc Fragments; D007370:Interferon Type I; D011994:Recombinant Proteins